Background: Diabetes Mellitus (DM) is a major chronic metabolic disorder characterized by hyperglycemia
that leads to several complications such as retinopathy, atherosclerosis, nephropathy, etc. In 2019, it
was estimated that about 463 million people had diabetes, and it may increase up to 700 million in 2045. Marine
macroalgae are the rich source of bioactive compounds for the treatment of diabetes mellitus.
Objective: This review summarizes the recent epidemiology and possible use of marine macroalgae-derived bioactive
compounds for the protection against chronic metabolic disease, diabetes mellitus and marine macroalgae
as a nutraceutical supplement.
Conclusion: The present therapies available for diabetes treatment are oral medicines and insulin injections.
But continuous use of synthetic medicines provides low therapeutic with many side effects. In continuing
search of anti-diabetic drugs, marine macroalgae remain as a promising source with potent bioactivity. Among
existing marine algae, red and brown algae are reported to show anti-diabetic activity. Hence, the present review
focuses on the epidemiology, diabetes biomarkers and different secondary bioactive compounds present in
marine macroalgae to treat diabetes mellitus.